Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Prime-Boost in Sickle Cell Disease
NCT02274415Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2013
- Primary completion
- Sep 2017
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of responders to at least 10 of thirteen serotypes at 8 weeks. Started Sep 2013; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02274415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274415.